SPDR S&P World ex-US ETF
Teva Has a Targeted Strategy to Expand in Major Growth Markets
In Russia, Teva Pharmaceutical has created a strong portfolio of about 300 products and has been extensively developing its research pipeline.
Teva’s Commercial Strategy May Be Successful across Europe
Teva Pharmaceutical (TEVA) currently operates in three types of markets in the European Union.
This Strategy Could Boost Teva’s Growth Prospects Even More
Excluding API sales, in 2016, Teva Pharmaceutical Industries is expected to earn about 50% of its net sales from the North American market.
Will Anda Acquisition Improve Access to Teva’s Generic Drugs?
On August 3, 2016, Teva Pharmaceutical (TEVA) announced that it will acquire Anda, Allergan’s pharmaceutical distributor business, for about $500 million.
How Is Teva Aiming to Lead the Abuse-Deterrent Opioid Segment?
Teva Pharmaceutical Industries (TEVA) expects Vantrela, an abuse-deterrent opioid, to be approved by the FDA in 2016.
What Can We Expect from Teva’s Respiratory Portfolio in 2016?
Teva Pharmaceutical Industries (TEVA) has been actively involved in developing and commercializing a breath-actuated dry-powder inhaler.